Compounds > beta-methyl-6-chloromelatonin
Page last updated: 2024-12-08

beta-methyl-6-chloromelatonin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID219018
CHEMBL ID4079759
SCHEMBL ID678611
MeSH IDM0472554

Synonyms (25)

Synonym
gtpl1351
tik-301
ly-156,735
ly156735
acetamide, n-((2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl)-
118702-11-7
n-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide
unii-3zx95b1zwk
3zx95b1zwk ,
beta-methyl-6-chloromelatonin
ly 156735
ly-156735
acetamide, n-(2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl)-, (r)-
pd-6735
n-((2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl)acetamide
SCHEMBL678611
pd-6735;ly-156735
DTXSID70922760
n-[2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]ethanimidic acid
HY-106136
Q6460405
CS-0024957
CHEMBL4079759
acetamide, n-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]-
AKOS040742743

Research Excerpts

Toxicity

Adverse events were mild to moderate in severity and did not differ in frequency between beta-methyl-6-chloromelatonin and placebo treatments. The incidence of all adverse events, the severity of the event or the event's relationship to treatment did not increase with higher doses.

ExcerptReferenceRelevance
" The incidence of all adverse events, the severity of the event or the event's relationship to treatment did not increase with higher doses of beta-methyl-6-chloromelatonin."( A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin.
Goldwater, DR; Mulchahey, JJ; Zemlan, FP, 2004)		0.72
" Adverse events were mild to moderate in severity and did not differ in frequency between beta-methyl-6-chloromelatonin and placebo treatments."( The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial.
Lankford, A; Mayleben, DW; Mulchahey, JJ; Rosenberg, R; Scharf, MB; Zemlan, FP, 2005)		0.8

Dosage Studied

ExcerptRelevanceReference
" The 10mg/kg supplementation demonstrated benefit; the 100mg/kg dosage was limited by toxicity."( Melatonin-analog, beta-methyl-6-chloromelatonin, supplementation in spinal cord injury.
Fee, DB; Gabbita, P; Roberts, K; Scheff, N; Scheff, S; Swartz, KR, 2010)		0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346220Human MT1 receptor (Melatonin receptors)2004Life sciences, Aug-27, Volume: 75, Issue:15
A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin.
AID1346274Human MT2 receptor (Melatonin receptors)2004Life sciences, Aug-27, Volume: 75, Issue:15
A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (37.50%)5.53%
Reviews3 (37.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (25.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
melatonin
[no description available]		7.6673acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
s20098
[no description available]		4.0520acetamides
sr141716
[no description available]		2.0210amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
ramelteon
ramelteon: melatonin MT1/MT2 receptor agonist		4.6730indanes
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		3.1610
tasimelteon
tasimelteon : A member of the class of 1-benzofurans that is propionamide in which one of the amide hydrogens is replaced by a [(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl group. A melatonin receptor agonist used for the treatment of non-24-hour sleep-wake disorder.		3.16101-benzofurans;
cyclopropanes;
monocarboxylic acid amide		melatonin receptor agonist
piperidines
Piperidines: A family of hexahydropyridines.		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Injuries, Spinal Cord
[description not available]		02.0510
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.0510
Chronic Insomnia
[description not available]		04.7521
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.		04.7521
Depression, Endogenous
[description not available]		02.9810
Depressive Disorder
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.		02.9810
Jet Lag
[description not available]		03.3911
Advanced Sleep Phase Syndrome
[description not available]		02.9310
Sleep Disorders, Circadian Rhythm
Dyssomnias associated with disruption of the normal 24 hour sleep wake cycle secondary to travel (e.g., JET LAG SYNDROME), shift work, or other causes.		02.9310
Acute Confusional Senile Dementia
[description not available]		02.9410
Long Sleeper Syndrome
[description not available]		02.9410
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.9410
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.9410
Sleep Wake Disorders
Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.		02.9410
Nicotine Addiction
[description not available]		02.0210
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.0210
Tobacco Use Disorder
Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.		02.0210
Smoking Cessation
Discontinuing the habit of SMOKING.		02.0210